New cream targets itch in eczema patients

NCT ID NCT07560618

Recruiting now Symptom relief Sponsor: Integrative Skin Science and Research Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 14, 2026 · Updated 3 times

Summary

This study tests a cream called roflumilast 0.15% for itching in people with mild to moderate atopic dermatitis (eczema). About 40 participants aged 12 and older will apply the cream once daily for 4 weeks. Researchers will track how patients describe their itch and other skin sensations using a smartphone app, and measure changes in itch severity over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Roflumilast 0.15% cream
What this could lead to: If successful, this could provide a new topical option to ease itching in atopic dermatitis and help doctors better understand how patients describe their skin sensations.
What could go wrong: This is a small, early-phase study with only 40 participants and no placebo group, so results may not apply broadly. The cream may not work for everyone or could cause skin irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema Mitchell syndrome Pruritus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS ITCH

Contacts and locations

Locations

Integrative Skin Science and Research
RECRUITING

Sacramento, California, 95815, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.